Welcome to the BMS portal for health care professionals!
This portal is your one-stop-shop for all your needs and questions concerning BMS products in Switzerland! These are some examples of the things you can find:
- Rich media library with webinars, podcasts, HCP materials, patient brochures and much more
- Detailed clinical data concerning our approved indications
- Information on ongoing clinical research in Switzerland
- Comprehensive calendar with BMS educational events and relevant national and international congresses
- The relevant BMS team members for your region and interest
Ready to explore? Please use your existing DocCheck Login to access one of our therapeutic area portals or to access the comprehensive BMS Medicines or News & Events overview
News and recent approvals
Genitourinary Cancer
August 2024 - OPDIVO® is now approved in combination with cisplatin/gemcitabine chemotherapy for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma with PD-L1 tumor expression ≥1%.
Gastrointestinal Cancer
March 2024 – OPDIVO® (nivolumab) in combination with chemotherapy containing oxaliplatin and fluoropyrimidine is indicated for the first-line treatment of adult patients with inoperable, locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, and distal oesophageal adenocarcinoma with Combined Positive Score (CPS) PD-L1 expression ≥ 10.
Melanoma
Februar 2024 – OPDUALAG® (nivolumab/relatlimab) is now reimbursed for the first-line treatment of adults with metastatic melanoma with PD-L1 < 1% expression.
Melanoma
November 2023 – Q4W 480 mg dosing with OPDIVO® (nivolumab) is approved in all melanoma indications.
Q4W dosing is approved for all Nivolumab monotherapy as well as monotherapy maintenance after Nivolumab + Ipilimumab combination treatment in melanoma.
Melanoma
October 2023 – OPDIVO® (nivolumab) as monotherapy is indicated for the adjuvant treatment of adults with completely resected Stage IIB or IIC melanoma.
Large B-Cell Lymphoma
September 2023 – Swissmedic approved BREYANZI® (lisocabtagene maraleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL) or primary mediastinal large B-cell lymphoma (PMBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.
BREYANZI®
▼ This drug is subject to additional monitoring. For further information, please refer to the information for healthcare professionals on swissmedicinfo.ch.
More information
03/2024 7356-CH-2400017